Holen Sie sich die Stockscreener-App
1.7935
0.76%
0.0135
Schlusskurs vom Vortag:
$1.78
Offen:
$1.79
24-Stunden-Volumen:
38,399
Relative Volume:
0.10
Marktkapitalisierung:
$6.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.47M
KGV:
-3.587
EPS:
-0.5
Netto-Cashflow:
$-13.51M
1W Leistung:
-3.83%
1M Leistung:
-17.35%
6M Leistung:
+19.57%
1J Leistung:
-62.40%
1-Tages-Spanne:
$1.7373
$1.8096
1-Wochen-Bereich:
$1.45
$1.9067
52-Wochen-Spanne:
$1.30
$5.6432
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Firmenname
Nls Pharmaceutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie NLSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.7746 | 7.57M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.44 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
477.53 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.98 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
813.12 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.30 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nls Pharmaceutics Ltd Aktie (NLSP) Neueste Nachrichten
Is NLS Pharmaceutics AG Equity Warrant stock reversal real or fakeEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Will NLS Pharmaceutics AG Equity Warrant stock outperform value stocksQuarterly Growth Report & Community Verified Trade Signals - newser.com
Custom watchlist performance reports with NLS Pharmaceutics AG Equity Warrant2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
Visualizing NLS Pharmaceutics AG stock with heatmaps2025 Price Momentum & Short-Term Swing Trade Alerts - newser.com
NLS Pharmaceutics AG Stock Analysis and ForecastCandlestick Pattern Analysis & Small Budget Investment Tips - earlytimes.in
Why NLS Pharmaceutics AG Equity Warrant stock is recommended by analystsJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Regression analysis insights on NLS Pharmaceutics AG Equity Warrant performanceJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
Combining machine learning predictions for NLS Pharmaceutics AGJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
What indicators show strength in NLS Pharmaceutics AG Equity WarrantJuly 2025 Sentiment & Stock Portfolio Risk Management - newser.com
Can a trend reversal in NLS Pharmaceutics AG lead to recoveryWeekly Stock Analysis & Free Community Supported Trade Ideas - newser.com
Is NLS Pharmaceutics AG a candidate for recovery playEarnings Overview Summary & Smart Money Movement Alerts - newser.com
Analyzing recovery setups for NLS Pharmaceutics AG Equity Warrant investors2025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
NLS Pharmaceutics files financial statements related to Kadimastem merger By Investing.com - Investing.com Nigeria
Will NLS Pharmaceutics AG Equity Warrant rebound enough to break evenGold Moves & Real-Time Stock Entry Alerts - newser.com
NLS Pharmaceutics files financial statements related to Kadimastem merger - Investing.com India
NLS Pharmaceutics Announces Strategic Merger with Kadimastem - TipRanks
Will NLS Pharmaceutics AG Equity Warrant bounce back from current supportQuarterly Trade Report & Real-Time Volume Analysis Alerts - newser.com
What’s next for NLS Pharmaceutics AG Equity Warrant stock priceQuarterly Earnings Report & Reliable Price Breakout Signals - newser.com
What to expect from NLS Pharmaceutics AG Equity Warrant in the next 30 daysJuly 2025 Rallies & AI Driven Stock Reports - newser.com
How NLS Pharmaceutics AG stock reacts to Fed rate cutsJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
Is NLS Pharmaceutics AG stock positioned well for digital economyWeekly Trend Recap & Technical Pattern Based Signals - newser.com
NLS Pharmaceutics Approve Merger with Kadimastem - citybiz
NLS Pharmaceutics stock tumbles after merger approval with Kadimastem By Investing.com - Investing.com Nigeria
NLS Pharmaceutics stock tumbles after merger approval with Kadimastem - Investing.com
NLSP Stock Faces Highs and Lows: A Closer Look - StocksToTrade
NLS Pharmaceutics Stock: What’s Next? - timothysykes.com
NLS Pharmaceutics shareholders approve merger with Kadimastem By Investing.com - Investing.com Australia
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem - TipRanks
NLS Pharmaceutics shareholders approve merger with Kadimastem - Investing.com India
NLS Pharmaceutics shareholders approve merger with Kadimastem and related proposals at extraordinary general meeting - MarketScreener
84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline - Stock Titan
Is NLS Pharmaceutics AG stock dividend yield sustainableWeekly Risk Summary & High Yield Equity Trading Tips - newser.com
NLS Pharmaceutics (NASDAQ:NLSP) Rating Increased to Hold at Wall Street Zen - Defense World
Visual trend scoring systems applied to NLS Pharmaceutics AG Equity WarrantJuly 2025 Price Swings & Accurate Buy Signal Alerts - newser.com
Using economic indicators to assess NLS Pharmaceutics AG Equity Warrant potentialWeekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
Is NLS Pharmaceutics AG stock ready for a breakoutTrade Analysis Summary & Weekly High Return Stock Opportunities - newser.com
Market reaction to NLS Pharmaceutics AG Equity Warrant’s recent newsJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Custom strategy builders for tracking NLS Pharmaceutics AGMarket Performance Report & AI Enhanced Market Trend Forecasts - newser.com
Rally Mode: Does NLS Pharmaceutics AG stock benefit from AI growthPrice Action & Low Risk Growth Stock Ideas - خودرو بانک
NLS Pharmaceutics Engages New Accounting Firm After Marcum’s Resignation - The Globe and Mail
Finanzdaten der Nls Pharmaceutics Ltd-Aktie (NLSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.86%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):